News

Article

NeurologyLive® Friday 5 — November 15, 2024

Key Takeaways

  • The FDA made several key decisions in October 2024, including drug approvals and clinical hold removals.
  • Abuse among multiple sclerosis patients is highlighted, revealing a troubling situation that requires attention.
SHOW MORE

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 15, 2024.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: FDA Action Update, October 2024: Approvals, Acceptance, and Hold Removal

The FDA was busy in October 2024, making a number of decisions on potential new therapeutic agents including granting approvals, accepting a resubmitted new drug application, and removing a clinical hold.

FDA Action Update, October 2024: Approvals, Acceptance, and Hold Removal

2: An IJMSC Spotlight On Caregivers, Individuals With Multiple Sclerosis, and Abuse

A feature on NeurologyLive®, IJMSC Insights offers a look at the data around abuse among patients with MS—which paint a clear and troubling picture.

An IJMSC Spotlight On Caregivers, Individuals With Multiple Sclerosis, and Abuse

3: Why Trump and Musk's Alliance Could Launch America's Neurotech Moonshot

Neal K. Shah, CEO at CareYaya Health Technologies, shared his perspective on how the new administration could unleash innovation in neurotech, reduce regulatory barriers with Elon Musk’s involvement, and accelerate innovations that could improve neurological care for those with Alzheimer and dementia.

Why Trump and Musk's Alliance Could Launch America's Neurotech Moonshot

4: NeuroVoices: David A. Hafler, MD, FANA, on Evolving the MS Diagnostic Criteria to Enhance Precision for Earlier and More Effective Care

In our latest Q&A for NeuroVoices, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed the newly updated multiple sclerosis criteria, highlighting their focus on probabilistic assessment, advanced technology integration, and early intervention to improve patient care.

NeuroVoices: David A. Hafler, MD, FANA, on Evolving the MS Diagnostic Criteria to Enhance Precision for Earlier and More Effective Care

5: What We Know But Still Have to Learn About Long COVID

Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.

What We Know But Still Have to Learn About Long COVID

Related Videos
2 experts in this video
Michael Levy, MD, PhD, is featured in this series.
2 experts in this video
Alexander C. Whiting, MD
2 experts in this video
2 experts in this video
© 2024 MJH Life Sciences

All rights reserved.